219 related articles for article (PubMed ID: 21514426)
1. Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma.
Bavi P; Uddin S; Ahmed M; Jehan Z; Bu R; Abubaker J; Sultana M; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Prabhakaran S; Hussain AR; Al-Kuraya KS
Am J Pathol; 2011 May; 178(5):2109-20. PubMed ID: 21514426
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
Uddin S; Ahmed M; Bavi P; El-Sayed R; Al-Sanea N; AbdulJabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Hussain AR; Al-Kuraya KS
Cancer Res; 2008 May; 68(9):3379-88. PubMed ID: 18451165
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer.
Uddin S; Ahmed M; Hussain AR; Jehan Z; Al-Dayel F; Munkarah A; Bavi P; Al-Kuraya KS
Lab Invest; 2009 Oct; 89(10):1115-27. PubMed ID: 19636294
[TBL] [Abstract][Full Text] [Related]
4. Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma.
Lin J; Raoof DA; Wang Z; Lin MY; Thomas DG; Greenson JK; Giordano TJ; Orringer MB; Chang AC; Beer DG; Lin L
Neoplasia; 2006 Dec; 8(12):1062-71. PubMed ID: 17217624
[TBL] [Abstract][Full Text] [Related]
5. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.
Shah SA; Potter MW; McDade TP; Ricciardi R; Perugini RA; Elliott PJ; Adams J; Callery MP
J Cell Biochem; 2001 Apr 2-27; 82(1):110-22. PubMed ID: 11400168
[TBL] [Abstract][Full Text] [Related]
6. Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib.
Loeffler-Ragg J; Mueller D; Gamerith G; Auer T; Skvortsov S; Sarg B; Skvortsova I; Schmitz KJ; Martin HJ; Krugmann J; Alakus H; Maser E; Menzel J; Hilbe W; Lindner H; Schmid KW; Zwierzina H
Mol Cancer Ther; 2009 Jul; 8(7):1995-2006. PubMed ID: 19567817
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines.
Baiz D; Dapas B; Farra R; Scaggiante B; Pozzato G; Zanconati F; Fiotti N; Consoloni L; Chiaretti S; Grassi G
World J Gastroenterol; 2014 Jan; 20(3):795-803. PubMed ID: 24574752
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitin-conjugating enzyme E2C: a potential cancer biomarker.
Xie C; Powell C; Yao M; Wu J; Dong Q
Int J Biochem Cell Biol; 2014 Feb; 47():113-7. PubMed ID: 24361302
[TBL] [Abstract][Full Text] [Related]
9. UBE2C is overexpressed in ESCC tissues and its abrogation attenuates the malignant phenotype of ESCC cell lines.
Palumbo A; Da Costa NM; De Martino M; Sepe R; Pellecchia S; de Sousa VP; Nicolau Neto P; Kruel CD; Bergman A; Nasciutti LE; Fusco A; Pinto LF
Oncotarget; 2016 Oct; 7(40):65876-65887. PubMed ID: 27588470
[TBL] [Abstract][Full Text] [Related]
10. P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.
Shirsath NP; Manohar SM; Joshi KS
Mol Cancer; 2012 Oct; 11():77. PubMed ID: 23075291
[TBL] [Abstract][Full Text] [Related]
11. CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability.
Wang H; Zhang C; Rorick A; Wu D; Chiu M; Thomas-Ahner J; Chen Z; Chen H; Clinton SK; Chan KK; Wang Q
Cancer Res; 2011 Jul; 71(14):4866-76. PubMed ID: 21593191
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
[TBL] [Abstract][Full Text] [Related]
13. Silencing ubiquitin-conjugating enzyme 2C inhibits proliferation and epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma.
Wang X; Yin L; Yang L; Zheng Y; Liu S; Yang J; Cui H; Wang H
FEBS J; 2019 Dec; 286(24):4889-4909. PubMed ID: 31715067
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1.
Hong YS; Hong SW; Kim SM; Jin DH; Shin JS; Yoon DH; Kim KP; Lee JL; Heo DS; Lee JS; Kim TW
Int J Oncol; 2012 Jul; 41(1):76-82. PubMed ID: 22552540
[TBL] [Abstract][Full Text] [Related]
15. UBE2C is a marker of unfavorable prognosis in bladder cancer after radical cystectomy.
Morikawa T; Kawai T; Abe H; Kume H; Homma Y; Fukayama M
Int J Clin Exp Pathol; 2013; 6(7):1367-74. PubMed ID: 23826418
[TBL] [Abstract][Full Text] [Related]
16. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
[TBL] [Abstract][Full Text] [Related]
17. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
[TBL] [Abstract][Full Text] [Related]
19. Depletion of UBE2C reduces ovarian cancer malignancy and reverses cisplatin resistance via downregulating CDK1.
Li J; Zhi X; Shen X; Chen C; Yuan L; Dong X; Zhu C; Yao L; Chen M
Biochem Biophys Res Commun; 2020 Mar; 523(2):434-440. PubMed ID: 31875843
[TBL] [Abstract][Full Text] [Related]
20. UBE2C promotes the progression of head and neck squamous cell carcinoma.
Jin Z; Zhao X; Cui L; Xu X; Zhao Y; Younai F; Messadi D; Hu S
Biochem Biophys Res Commun; 2020 Mar; 523(2):389-397. PubMed ID: 31870550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
